Fundamental Analysis of SUTRO BIOPHARMA INC(NASDAQ:STRO) stock

Fundamental Rating

Overall STRO gets a fundamental rating of 4 out of 10. We evaluated STRO against 587 industry peers in the Biotechnology industry. STRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. STRO is valued quite expensively, but it does show have an excellent growth rating.

Quickly go to:

1. Profitability

1.1 Basic Checks

STRO had negative earnings in the past year.

In the past year STRO has reported a negative cash flow from operations.

In the past 5 years STRO always reported negative net income.

In the past 5 years STRO reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of STRO (-22.68%) is better than 79.32% of its industry peers.

STRO has a Return On Equity of -71.36%. This is comparable to the rest of the industry: STRO outperforms 54.87% of its industry peers.

		Industry Rank	Sector Rank
ROA	-22.68%
ROE	-71.36%
ROIC	N/A

ROA(3y)-27.63%

ROA(5y)-25.34%

ROE(3y)-56.02%

ROE(5y)-46.95%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for STRO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

STRO does not have a ROIC to compare to the WACC, probably because it is not profitable.

STRO has more shares outstanding than it did 1 year ago.

STRO has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, STRO has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -0.49, we must say that STRO is in the distress zone and has some risk of bankruptcy.

STRO has a Altman-Z score of -0.49. This is comparable to the rest of the industry: STRO outperforms 57.78% of its industry peers.

There is no outstanding debt for STRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-0.49

ROIC/WACCN/A

WACC9.08%

2.3 Liquidity

STRO has a Current Ratio of 4.50. This indicates that STRO is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of STRO (4.50) is comparable to the rest of the industry.

STRO has a Quick Ratio of 4.50. This indicates that STRO is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of STRO (4.50) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	4.5
Quick Ratio	4.5

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.05% over the past year.

The Revenue has grown by 126.79% in the past year. This is a very strong growth!

The Revenue has been growing by 31.96% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)27.05%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q176.47%

Revenue 1Y (TTM)126.79%

Revenue growth 3Y53.24%

Revenue growth 5Y31.96%

Revenue growth Q2Q1217.74%

3.2 Future

The Earnings Per Share is expected to grow by 19.12% on average over the next years. This is quite good.

The Revenue is expected to grow by 50.03% on average over the next years. This is a very strong growth

EPS Next Y-89.22%

EPS Next 2Y-36.66%

EPS Next 3Y-16.78%

EPS Next 5Y19.12%

Revenue Next Year6.26%

Revenue Next 2Y19.14%

Revenue Next 3Y27.03%

Revenue Next 5Y50.03%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

STRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year STRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as STRO's earnings are expected to decrease with -16.78% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-36.66%

EPS Next 3Y-16.78%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

STRO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SUTRO BIOPHARMA INC

NASDAQ:STRO (5/10/2024, 7:21:09 PM)

After market: 4.15 0 (0%)

4.15

-0.2 (-4.6%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap339.30M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-22.68%
ROE	-71.36%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.33

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.5
Quick Ratio	4.5
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)27.05%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-89.22%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)126.79%

Revenue growth 3Y53.24%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

SUTRO BIOPHARMA INC (STRO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens